Azathioprine Increases the Risk of Non‐Melanoma Skin Cancer Among Organ Transplant Recipients; an Updated Systematic Review and Meta‐Analysis
Open Access
- 10 February 2026
- journal article
- review article
- Published by Wiley in Cancer Reports
- Vol. 9 (2) , e70473
Abstract
Background: Azathioprine (AZA) is a purine antimetabolite immunosuppressant that prevents the body from rejecting transplanted organs and is used in organ transplant recipients (OTRs). This study aimed to conduct a meta‐analysis to determine whether AZA usage has an increased risk of skin cancer in OTRs. Methods: To explore the association between AZA usage and skin cancer through observational studies we conducted a systematic search across PubMed, Scopus, and Web of Science databases. A random effects model, subgroup analysis, and heterogeneity assessment were used for meta‐analysis. The quality of the included studies was assessed using the Newcastle Ottawa scale checklist. Results: A total of 27 studies with 21 405 patients were included to the quantitative analysis. the overall summary estimate for non‐melanoma skin cancer (NMSC) risk in relation to AZA treatment according Odds ratio (OR) estimates, relative risk (RR) estimates and hazard ratio (HR) estimates were 1.83 (95% confidence interval (CI): 1.22, 2.75), 2.09 (CI: 1.41, 3.10), and 1.12 (CI: 0.93, 1.34), respectively. There was a substantial heterogeneity between studies in all types of OR estimates (I2 = 80.75%), RR estimates (I2 = 65.58%) and HR estimates (I2 = 54.63%). In the subgroup analysis, there was a significant increase in squamous cell carcinoma (SCC) risk in all three estimate effects while regarding basal cell carcinoma (BCC) none of them were significant. Conclusion: Our findings indicate that OTRs treated with AZA are at an increased risk for SCC and NMSC. Therefore, it is recommended to prioritize monitoring for skin cancer in OTRs treated with AZA.Keywords
Funding Information
- Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences (140311029895)
This publication has 40 references indexed in Scilit:
- Immune Phenotype Predicts Risk for Posttransplantation Squamous Cell CarcinomaJournal of the American Society of Nephrology, 2010
- Incidence of and Risk Factors for Skin Cancer After Heart TransplantArchives of Dermatology, 2009
- First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipientsNephrology Dialysis Transplantation, 2009
- Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinomaNephrology Dialysis Transplantation, 2009
- Cancer Incidence and Survival in Kidney Transplant PatientsTransplantation Proceedings, 2008
- Non‐melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapyInternational Journal of Dermatology, 2008
- A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipientsBritish Journal of Dermatology, 2003
- Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, AustraliaJournal of the American Academy of Dermatology, 2003
- Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimensJournal of the American Academy of Dermatology, 1999
- THE RISK OF SKIN CANCER IN RENAL TRANSPLANT RECIPIENTS IN QUEENSLAND, AUSTRALIATransplantation, 1996